Dostarlimab is being considered for the treatment of primary advanced or recurrent endometrial cancer. The treatment, often used in combination with chemotherapy, has shown potential for disease control in certain patients, although the balance of benefits and risks is being weighed. Dostarlimab has been recommended or reimbursed by some authorities, including in certain regions of canada, for use in adult patients with this type of cancer.